Abstract TGF-β1 is a main inducer of epithelial to mesenchymal transition (EMT). However, many breast cancer cells are not sensitive to the EMT induction by TGF-β1 alone. So far, the mechanisms underlying the induction of TGF-β1-insensitive breast cancer cells remains unclear. Here we report that TNF-α can induce EMT and invasiveness of breast cancer cells which are insensitive to TGF-β1. Intriguingly, TGF-β1 could cooperate with TNF-α to promote the EMT and invasiveness of breast cancer cells. The prolonged co-stimulation with TGF-β1 and TNF-α could enhance the sustained activation of Smad2/3, p38 MAPK, ERK, JNK and NF-κB pathways by enhancing the activation of TAK1, which was mediated by the gradually up-regulated TβRs. Except for JNK, all of these pathways were required for the effects of TGF-β1 and TNF-α. Importantly, the activation of p38 MAPK and ERK pathways resulted in a positive feed-back effect on TAK1 activation by up-regulating the expression of TβRs, favoring the activation of multiple signaling pathways. Moreover, SLUG was up-regulated and required for the TGF-β1/TNF-α-induced EMT and invasiveness. In addition, SLUG could also enhance the activation of signaling pathways by promoting TβRII expression. These findings suggest that the up-regulation of TβRs contributes to the sustained activation of TAK1 induced by TGF-β1/TNF-α and the following activation of multiple signaling pathways, resulting in EMT and invasiveness of breast cancer cells.
Introduction
Epithelial-mesenchymal transition (EMT) is intently related to the metastasis of breast cancer. Tumor cells that have undergone EMT could acquire the ability to disseminate from primary epithelial tumors (Foroni et al. 2012; Thiery 2002) . EMT cells are responsible for degrading the surrounding matrix to enable invasion and intravasation of both EMT and non-EMT cells (Tsuji et al. 2009 ). It has been known that the inflammatory factors that exist in the tumor milieu could induce EMT of tumor cells (Soria et al. 2011) . Although several inflammatory cytokines can induce EMT, many cells undergo EMT only in the presence of multiple cytokines (Gardner et al. 2012; Said and Williams 2011; Uttamsingh et al. 2007; Yamauchi et al. 2010; Yan et al. 2018) , suggesting that different cytokines may act synergistically to induce EMT. Therefore, exploring the mechanism underlying the synergistic effect of different cytokines will lead to better understanding the initiation of EMT.
TGF-β1 is a multi-functional cytokine that is abundantly expressed in many epithelial tumors to promote tumor malignancy (de Caestecker et al. 2000) . It is well accepted that TGF-β1 is the best characterized EMT inducer (Xu et al. 2009 ). However, TGF-β1 alone could not induce EMT in many breast cancer epithelial cells, presumably because it does not effectively activate the Smad pathway in these cells (Brown et al. 2004; Zhou et al. 2013 ). In addition, TNF-α is another widely studied cytokine that induces EMT in many epithelial cells as well (Bates and Mercurio 2003; Chuang et al. 2008; . TNF-α is secreted mainly by tumor-associated macrophages that can also promote tumor growth (Balkwill 2006) . Previous studies showed that TNF-α could accelerate TGF-β1-induced EMT in tumor cells, although TNF-α alone can also induce EMT in these cells (Bates and Mercurio 2003; Yamauchi et al. 2010) . However, it is unclear whether TNF-α is able to induce EMT in TGF-β1-insensitive breast cancer cells, and whether TNF-α and TGF-β1 have synergistical effect to induce EMT in these cells.
The efficient activation of signaling pathways is the important driving force of cytokine-induced EMT. Smad2/3 is the canonical pathway of TGF-β signaling and plays a critical role in the TGF-β1-induced EMT and tumor development (Do et al. 2008; Gupta et al. 2011) . In parallel, TGF-β1 also activates non-Smad pathways such as those depending on MAPK and NF-κB (Zhang 2009 ). In fact, MAPK and NF-κB signaling pathways were all reported to participate in the TGF-β1-induced EMT (Huber et al. 2004; Pechkovsky et al. 2008) . In addition, NF-κB is a canonical pathway of TNF-α signaling, which is also required for the TNF-α-induced EMT and invasiveness of tumor cells (Maier et al. 2010; . Interestingly, TGF-β activated kinase 1 (TAK1), one of MAPKKKs, plays a critical role both in nonSmad pathway of TGF-β1 and canonical pathway of TNF-α. The activated TAK1 can activate MAPKs and NF-κB through MAPKKK/MAPKK/MAPK and IKK/IκBα pathways, respectively (Landstrom 2010) . Concurrently, TAK1 was reported to be involved in the TGF-β1-induced and TNF-α-accentuated EMT by modulating multiple signaling pathways in mesothelial cells and bronchial epithelial cells (Gardner et al. 2012; Strippoli et al. 2012) , suggesting that TAK1 might be a core factor for the effect of TGF-β1 and TNF-α. In this study, we investigated whether TNF-α, alone or together with TGF-β1, could induce EMT of breast cancer epithelial cells, and the role of TAK1 in the induction process. Our data showed that TNF-α alone could induce EMT of breast cancer epithelial cells and enhance the responsiveness of TGF-β1-insensitive cells by promoting TβRs expression. In turn, TGF-β1 cooperates with TNF-α to enhance the activation of multiple signaling pathways by enhancing TAK1 activation, thus promoting the EMT and invasiveness of tumor cells.
Materials and methods

Cells and reagents
Human breast cancer cell lines MCF-7 and T-47D were purchased from china center for type culture collection (CCTCC, Wuhan, china), and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Human TNF-α and TGF-β1 were purchased from PeproTech (Rocky Hill, NJ). Matrigel was purchased from BD Biosciences (Bedford, MA, USA). SB203580, PD98059, SP600125, SIS3, (5Z)-7-oxozeaenol, 6-amino-4-(4-phenoxyphenyl-ethylamino) quinazoline (QNZ) were purchased from Merck4 Bioscience (Calbiochem, Germany). All inhibitors were dissolved in DMSO as a stock solution and diluted with culture medium to the desired concentration without toxicity to cells.
Real-time RT-PCR
Total RNA was extracted from cells with TRIzol reagent (Invitrogen, Carlsbad, CA). The relative quantity of the indicated mRNA to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was determined by real-time RT-PCR assays as described previously (Liao et al. 2012) , Briefly, 100 ng of total RNA was used for reverse transcription using SuperscriptIIRNase H reverse transcriptase (Invitrogen, Carlsbad, CA) in a volume of 25 μL. Then, 2 μL of cDNA was amplified with SYBR Green Universal PCR Mastermix (Bio-Rad, Richmond, CA) in duplicate. For sample analysis, the threshold was set based on the exponential phase of products, and C T value for samples was determined. The resulting data were analyzed with the comparative C T method for relative gene expression quantification against house keeping gene GAPDH. The primer sequences were as follows: MMP9, sense 5′-CAGTCCACCCTTGTGCTCTTCC-3′, antisense 5′-CTGCCAC CCGAGTGTAACCAT-3′; GAPDH, sense 5′-TCATTGACCTCAACTACATGGTTT-3′, antisense 5′-GAAGATGGTG ATGGGATTTC-3′; TGF-βRI, sense 5′-TGAACAGAAGTT AAGGCCAAATATC-3′, anti sense 5′-CAGGCAAAGCTGTAGAATTACATTT-3′; TGF-βRII, sense 5′-CGGTTAATAACGACATGATAGTCAC-3′, antisense 5′-TCATGGCAAACTGTC TCTAGTGTTA-3′; SNAIL, sense 5′-ACCTTCCAGCAGCCCTAC-3′, antisense 5′-CCTTTCC CACTGTCCTCAT-3′; SLUG, sense 5′-AGGAATCTGGCTGCTGTG-3′, antisense 5′-GGAG AAAATGCCTTTGG AC-3′; TWIST1, sense 5′-GAGT C C G C A G T C T TA C G A G -3 ′ , a n t i s e n s e 5 ′ -T G A G GGTCTGAATCTTGCT-3′; ZEB1, sense 5′-ACAC CTTTGCATACAGAACCC-3′ antisense 5′-ACACC CAGACTGCGTCACAT-3′.
Western blot assay
Western blot assay was done as described previously (Liao et al. 2012) . In brief, harvested cells were lysed in lysis buffer contained protease cocktail inhibitors. The cell extract was separated by SDS-polyacrylamide gel electrophoresis, and transferred to nitrocellulose membranes. After blocking with TBST (Tris-buffered saline with 0.05% Tween-20) containing 5% nonfat milk, the membranes were incubated with antibodies against human p-TAK1 (Thr187, #4536), TAK1 (#4505), p-Smad3 (Ser423/425, sc-130,218), Smad3 (sc-101,154), pSmad2 (Ser467, sc-101,801), Smad2 (sc-101,153), pp38MAPK (Thr180/Tyr182, sc-17,852-R), p38MAPK (sc-81,621), p-ERK1/2 (Thr202/Tyr204, #9101), ERK1/2 (#9102), p-JNK (Thr183/Tyr185, #9255), JNK (#9252), Ecadherin (sc-31,020), vimentin (sc-6260), TGF-βRI (sc-518,018), 791), 476 ) and β-actin (sc-1616). All antibodies were purchased from Santa cruz biotechnology (sc-) and cell signaling technology company (#). After incubation with the secondary antibody conjugated with horseradish peroxidase, membranes were extensively washed, and the immunoreactivity was visualized by enhanced chemiluminescence according to the manufacturer's protocol (ECL kit; Santa Cruz Biotechnology, Santa Cruz, CA).
Matrigel invasion assay
Invasion assay was performed using Boyden chambers (Transwell, Corning, Inc., Corning, NY) . The transwell filter inserts were coated with matrigel. The lower chambers were filled with DMEM medium containing 10% FBS. 1 × 10 5 tumor cells were placed in the upper compartment. After 24-h incubation at 37°C in a humidified incubator with 5% CO 2 , the non-invasive cells were removed. The cells attached to the lower surface of the membrane insert were fixed, stained, and counted under a microscope from five randomly chosen fields in each membrane. The average number of the cells per fields was calculated.
Cell transduction
Control shRNA lentiviral particles (sc-108,080), TβRI lentiviral particles (sc-40,222-V), TβRII shRNA lentiviral particles (sc-36,658-V) and SLUG shRNA lentiviral particles (sc-38,393-V) were all purchased from Santa Cruz Biotechnology (sc-). To down regulate TβRI or TβRII or SLUG in tumor cells, the cells were transduced with corresponding shRNA lentiviral particles according to the manufacturer's protocol. After selection with puromycin, the cells were used for further experiments.
NF-κB activity assay
The nuclear extract was prepared with Nuclear Extraction Kit (Millipore, Billerica, MA). The activity of NF-κB in nuclear extract was determined by NF-κB Assay Kit (Millipore, Billerica, MA) according to the manufacturer's protocol. In brief, cells were harvested and added cytoplasmic lysis buffer to separate the cytoplasmic protein and nucleus. The nuclear proteins from nucleus were extracted by using nuclear extraction buffer. The nuclear proteins, biotinylated double stranded oligonucleotide NF-kB capture probe and transcription factor assay buffer were mixed. The mixture was first incubated in a streptavidin-coated plate. After further incubation with primary antibody against NF-kB p50 or p65, and then incubation with a highly sensitive HRP-conjugated secondary antibody, the substrate TMB was added for detection. Last, the absorbance value was detected in a spectrophotometric plate reader with a standard OD 450 filter.
Actin polymerization analysis
Tumor cells were incubated in matrigel-coated plate for 5 h. The cells were then fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and then stained with rhodamine-phalloidin (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol to visualize the cells with highly polymerized actin.
MMP assay by gelatin zymography
Tumor cells were cultured for 48 h in DMEM medium containing 1% FBS in presence of pre-coated matrigel. The assay of MMP-9 in supernatants was performed as described previously (Liao et al. 2012) .
Statistics
Results were expressed as mean ± SD and interpreted by oneway ANOVA. Differences were considered to be statistically significant when P < 0.05.
Results
TGF-β1 cooperates with TNF-α to induce EMT and invasion in non-invasive breast cancer epithelial cells
To investigate whether TGF-β1 and TNF-α could induce EMT of non-invasive breast cancer epithelial cells, we cultured non-invasive MCF-7 and T-47D cells in presence of TGF-β1 and TNF-α for different days, and detected the protein level of epithelial marker E-cadherin and the mesenchymal marker vimentin. The results showed that the expression of E-cadherin was gradually down-regulated, while vimentin was gradually up-regulated both in MCF-7 and T-47D cells during prolonged stimulation (Fig. 1a) . Coincidentally, the invasive ability of TGF-β1/TNF-α-co-stimulated cells was gradually increased (Fig. 1b) . Next, we treated MCF-7 and T-47D cells with TGF-β1 and TNF-α, alone or in combination, for 6 days. TGF-β1 alone did not influence the morphology and the expression levels of E-cadherin and vimentin in these cells (Fig. 1c) . However, tumor cells treated with TNF-α alone displayed a fibroblast-like morphology, accompanied with decreased-expression of E-cadherin and increasedexpression of vimentin (Fig. 1c) . Intriguingly, although TGF-β1 alone had no effect, co-application of TGF-β1 and TNF-α induced more pronounced fibroblast-like morphological changes as well as changes in the E-cadherin and vimentin expression than TNF-α applied alone (Fig. 1c) . Furthermore, co-stimulation also increased the invasive ability of these cells, while TGF-β1 alone had no effect (Fig. 1e) . Consistently, co-application also increased the proportion of highly polymerized F-actin ( Fig. 1d ) and the expression and secretion of MMP-9 (Fig. 1f) , which could facilitate the invasive ability of tumor cells. These results indicated that TGF-β1 could synergistically enhance the effects of TNF-α on EMT induction and invasion in non-invasive breast cancer epithelial cells.
TGF-β1 cooperates with TNF-α to augment the sustained activation of Smad3, MAPKs and NF-κB signaling pathways
The requirement for prolonged stimulation implied that the sustained activation of signaling pathways might be important for TGF-β1 and TNF-α to effectively induce an EMT and invasive phenotype of non-invasive breast cancer cells. We therefore analyzed the activation of signaling pathways that might be potentially involved in the effect of TGF-β1 and TNF-α. The results showed that the long-lasting co-stimulation with TGF-β1 and TNF-α gradually enhanced the sustained activation of Smad2, Smad3, p38 MAPK, ERK, JNK and NF-κB ( Fig. 2a and b) . Next, we compared the effect of TGF-β1 and TNF-α, alone or in combination, in activating these signaling pathways after long-lasting stimulation. TGF-β1 could induce a weak sustained activation of Smad2 and Smad3, while TNF-α did not influence the phosphorylation of Smad2 and Smad3 (Fig. 2c) . TNF-α alone, but not TGF-β1 alone, efficiently induced the sustained activation of p38 MAPK, ERK, JNK and NF-κB ( Fig. 2d and e) . Intriguingly, co-stimulation with TGF-β1 and TNF-α induced a significantly enhanced activation of all of these signaling pathways ( Fig. 2d and e). These results suggested that the prolonged co-stimulation with TGF-β1 and TNF-α is required not only for the sustained activation of Smad pathway but also for a more efficiently activation of p38 MAPK, ERK, JNK and NF-κB pathways.
The enhanced activation of multiple signaling pathways are modulated by TAK1 during prolonged co-stimulation
To explore the mechanisms underlying the gradually enhanced activation of multiple signaling pathways by TGF-β1 and TNF-α, we focused on TAK1, which is potentially involved in both TGF-β1 and TNF-α signaling (Landstrom 2010; Sakurai et al. 2003) . The results showed that co-stimulation with TGF-β1 and TNF-α gradually enhanced the sustained activation of TAK1 (Fig. 3a) . TGF-β1 alone was inefficient in inducing TAK1 activation, while TNF-α alone effectively activated TAK1 (Fig. 3b) . Intriguingly, co-application of TGF-β1 and TNF-α was more efficient in inducing the activation of TAK1 (Fig. 3b) . The similar dynamic change of TAK1 activation and the activation of Smad3, NF-κB and MAPKs implied that there may be linkage among them. To identify this, we treated MCF-7 cells with TGF-β1 and TNF-α in presence of (5Z)-7-oxozeaenol which specifically inhibits TAK1 activation (Fig. 3c) . The results showed that the sustained activation of Smad2, Smad3, MAPKs, and NF-κB were all significantly attenuated in the presence of (5Z)-7-oxozeaenol ( Fig. 3c and d) . These results suggested that the TGF-β1/TNF-α-induced activation of Smad2/3, NF-κB and MAPKs were all modulated by TAK1. Then we wondered whether these TAK1-modulated Fig. 1 TGF-β1 cooperates with TNF-α to induce EMT and invasiveness in non-invasive breast cancer cells. a and b MCF-7 and T-47D cells were cultured in presence of TGF-β1 (10 ng/ml) and TNF-α (10 ng/ml) for the indicated time. The expression of E-cadherin, vimentin and β-actin was detected by Western blot (a) and used for Matrigel invasion assay (b). c-f MCF-7 and T-47D cells were cultured in presence of TGF-β1 and/or TNF-α for 6 days. The cells were then used for the following experiments. c The morphology of cells was photographed under an inverted phase contrast microscope (left). The scale bar represents 50 μm. The expression of E-cadherin and vimentin of cells were detected by Western blot (right). Data are the representatives of three independent experiments. d The cells were then cultured in presence of matrigel for 5 h. Cell F-actin was visualized by staining with rhodaminephalloidin (red). Cell nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI, blue) (left). Arrows indicate representative cells with highly polymerized actin. The scale bar represents 25 μm. The percentage of cells with highly polymerized actin in total cells was calculated (right). e The cells were used for Matrigel invasion assay. f The cells were then cultured in presence of matrigel for 48 h. The expression of MMP-9 was detected by real-time RT-PCR (left). The MMP-9 in supernatants was detected by zymography assay, and the fold difference of active MMP-9 was calculated after densitometric analysis of the gel (right). P values, * P < 0.05, **P < 0.01 pathways might influence the activation of TAK1. To ascertain this, we detected the phosphorylation level of TAK1 after stimulation with TGF-β1 and TNF-α in presence of SIS3 (Smad3 inhibitor), QNZ (NF-κB inhibitor), SB203580 (p38MAPK inhibitor), PD98059 (ERK pathway inhibitor), or SP600125 (JNK inhibitor) ( inhibitor and p38 MAPK inhibitor were most effective in suppressing the sustained activation of TAK1. In addition, Smad3 inhibitor or NF-κB inhibitor slightly attenuated TAK1 activation. However, inhibiting JNK did not influence the activation of TAK1. These results suggested that the activation of ERK and p38 MAPK may have positive feed-back effect to promote the sustained activation of TAK1.
TAK1 activation is enhanced by gradually up-regulated TGF-β receptors during long-lasting co-stimulation
To further investigate the mechanisms underlying the gradual activation of TAK1, we analyzed whether the expression of TGF-β1 receptors and TNF-α receptors were influenced by TGF-β1 and TNF-α. The results showed that the mRNA expressions of TβRI and TβRII were gradually increased during co-stimulation with TGF-β1 and TNF-α ( Fig. 4a and b) . However, the expression of TNFRI and TNFRII were not significantly changed after co-stimulation (data not shown). TGF-β1 alone could not influence the expression of its receptors. Intriguingly, TNF-α alone promoted the expression of TβRI and TβRII, and co-application of TGF-β1 further upregulated the expression of these receptors (Fig. 4a-c) . We then analyzed whether signaling pathways were involved in modulating the expression of TGF-β receptors. To do this, we detected the mRNA expressions of TβRI and TβRII after stimulation with TGF-β1 and TNF-α in presence of SIS3, QNZ, SB203580, PD98059, or SP600125. The results showed that the up-regulation of TβRI and TβRII was suppressed when inhibiting p38 MAPK or ERK pathway (Fig. 4d) . Considering that inhibiting these pathways also decreased TAK1 activation, we then investigated whether TβRI or TβRII were involved in the enhanced activation of TAK1 during prolonged co- Fig. 2 TGF-β1 cooperates with TNF-α to augment the sustained activation of Smad3, MAPKs and NF-kB signaling pathways. a and b MCF-7 cells were stimulated with TGF-β1 (10 ng/ml) and TNF-α (10 ng/ml) for the indicated time. a The phospho-Smad3, Smad3, phospho-Smad2, Smad2, phosphop38 MAPK, p38 MAPK, phospho-ERK1/2, ERK1/2, phospho-JNK and JNK were detected by Western blot assay. b The activity of NF-κB was assayed as described in Methods. (C-E) MCF-7 cells were stimulated with TGF-β1 and/or TNF-α for 6 days. c The phosphoSmad3, Smad3, phospho-Smad2 and Smad2 were detected by Western blot assay (left). The ratio of phosphorylated protein to total protein of the indicated proteins were calculated after densitometric analysis of the blots (right). d The phospho-p38 MAPK, p38 MAPK, phospho-ERK1/2, ERK1/2, phospho-JNK and JNK were detected by Western blot assay (left). The ratio of phosphorylated protein to total protein of the indicated proteins were calculated after densitometric analysis of the blots (right). e The activity of NF-κB was assayed as described in Methods. Data are representative of three independent experiments, or pooled from three independent experiments. P values, * P < 0.05, **P < 0.01 stimulation. To do it, we silenced TβRI or TβRII by transducting the shRNA lentiviral particles (Fig. 4e) . Intriguingly, silencing TβRI or TβRII not only attenuated the activation of TAK1 but also decreased the sustained activation levels of Smad2, Smad3, MAPKs and NF-κB ( Fig. 4f-h ). These results suggested that the up-regulated TβRs contribute to the enhanced activation of TAK1, which is required for the subsequent activation of down-stream signaling pathways.
The sustained activation of signaling pathways and up-regulated SLUG are required for the co-stimulation-induced EMT and invasion of non-invasive breast cancer cells
To ascertain the molecular basis underlying the TGF-β1/ TNF-α-mediated induction of EMT and invasion process, we next analyzed whether the activated signaling pathways Phospho-TAK1 and TAK1 were detected by Western blot (left). Relative phosphorylation of TAK1 was calculated after densitometry assay (right). b MCF-7 cells were cultured in presence of TGF-β1 and/or TNF-α for 6 days. Phospho-TAK1 and TAK1 were detected by Western blot (left). Relative phosphorylation of TAK1 was calculated after densitometry assay (right). c MCF-7 cells were cultured in presence of TGF-β1/TNF-α with or without (5Z)-7-oxozeaenol (TAK1 inhibitor, 600 nM) for 6 days. The Phospho-TAK1, TAK, PhosphoSmad3, Smad3, Phospho-p38 MAPK, p38 MAPK, phospho-ERK1/2, ERK1/2, phospho-JNK and JNK were detected by Western blot. d MCF-7 cells were cultured in presence of TGF-β1/TNF-α with or without (5Z)-7-oxozeaenol or QNZ (NF-κB inhibitor, 40 nM) for 6 days. The activity of NF-κB was assayed as described in Methods. e MCF-7 cells were untreated or treated for 6 days with TGF-β1/TNF-α in absence or presence of SIS3 (10 μM), QNZ (40 nM), SB203580 (SB, 10 μM), PD98059 (PD, 10 μM), SP600125 (SP, 10 μM). The phospho-TAK1 and TAK1 were detected by Western blot (left). The ratio of phospho-TAK1 and TAK1 was calculated after densitometry analysis of Western blots (right). Data are representative of three independent experiments, or pooled from three independent experiments. P values, * P < 0.05, **P < 0.01 .004
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. are required for the effects of co-stimulation. To do this, we cultured MCF-7 cells with TGF-β1 and TNF-α in presence of (5Z)-7-oxozeaenol, SIS3, QNZ, SB203580, PD98059, or SP600125. The results showed that inhibiting TAK1 nearly abolished the effects of TGF-β1/TNF-α-induced downregulation of E-cadherin, up-regulation of vimentin and invasiveness in MCF-7 cells ( Fig. 5a and b) . The ERK1/2, p38 MAPK, Smad3 and NF-κB pathways were all involved in the effects of TGF-β1 and TNF-α ( Fig. 5c and d) . Among them, ERK1/2 and p38 MAPK pathway were more efficient than Smad3 and NF-κB pathway. However, JNK pathway had no effect ( Fig. 5c and d) . These results suggested that the sustained activation of multiple signaling pathways is indeed required for TGF-β1/TNF-α-induced EMT and invasion of breast cancer cells. Considering that EMT-related transcriptional factors directly contribute to the EMT process, we then detected the mRNA expression of SNAIL, SLUG, ZEB1 and TWIST1 factors that intently related to EMT after co-stimulation with TGF-β1 and TNF-α. Among them, the expression of SLUG was increased most significantly, while the expression of ZEB1 was slightly up-regulated, but the expression of TWIST1 and SNAIL was not significantly changed (Fig. 5e) . Consistently, both Smad and ERK pathway are reported to be involved in up-regulating SLUG (Joseph et al. 2009; Xu et al. 2009 ). TGF-β1 and TNF-α could induce the sustained activation of these pathways, thus promoting the expression of SLUG. Moreover, SLUG could promote the expression of TβRII (Dhasarathy et al. 2011) , which forms a positive feed-back effect to further promote signaling pathways. Next, we knocked down SLUG in MCF-7 cells through transducing SLUG shRNA lentiviral particles ( Fig. 5f and g) . Intriguingly, the effect of TGF-β1/ TNF-α on EMT and invasion of MCF-7 cells was abolished after silencing SLUG (Fig. 5f-h ), suggesting that SLUG is required for the effects of co-stimulation.
Discussion
Both TGF-β1 and TNF-α exist in tumor microenvironment due to the inflammatory responses (Singh et al. 2016) . They could induce EMT and enhance metastatic potential of tumor cells. In this study, we found that TGF-β1 alone could not induce EMT in non-invasive breast cancer cells, MCF-7 and T-47D, in agreement with previous reports (Brown et al. 2004 ). However, we identified that TNF-α alone could induce EMT and invasion in MCF-7 and T-47D cells, which has not been reported in TGF-β1-insensitive cells. Importantly, coapplication of TGF-β1 and TNF-α synergistically induce EMT and invasion in these cells as well as in TGF-β1-sensitive cells (Yamauchi et al. 2010; Yan et al. 2018) .
Both Smad and non-Smad pathways are involved in the TGF-β1-induced EMT and metastatic potential of tumor cells (Meulmeester and ten Dijke 2011; Zhou et al. 2013) . Our data and previous report showed that the expression of TGF-β receptors is very low in MCF-7 and T-47D cells (Zhou et al. 2013) . In line with this, TGF-β1 could not induce the sustained activation of not only Smad but also non-Smad pathways in MCF-7 and T-47D cells, which may explain why TGF-β1 could not induce EMT in non-invasive breast cancer cells. However, TNF-α could promote the expression of both TGF-βRI and TGF-βRII by activating ERK1/2 and p38 MAPK signaling pathways. The up-regulation of TβRs increased the response of the cells to TGF-β1. In turn, the coapplication with TGF-β1 could further enhance these signaling pathways. The enhanced activation of these pathways forms a positive feed-back regulation to further promote the effect of TGF-β1 by up-regulating TGF-β receptors. In this context, TGF-β1/TNF-α-induced EMT and invasiveness of breast cancer cells need prolonged co-stimulation, since the TGF-β receptors were gradually increased.
TAK1 was first identified as a member of TGF-β signaling family that mediates the activation of JNK and p38 MAPK (Yamaguchi et al. 1995) . It has been known that TGF-β specifically activates TAK1 through interaction of TβRI with TRAF6, and TNF-α activates TAK1 through TRAF2/5 (Landstrom 2010; Sakurai et al. 2003) . Additionally, TAK1 is also involved in TGF-β1-or TNF-α-induced the activation of NF-κB through TAK1/IKK/IκB signaling pathway (Li et al. 2012, Neil and Schiemann 2008) . Our data in this study showed that TNF-α alone was more efficient in inducing TAK1 activation than TGF-β1 alone, and that co-stimulation with TNF-α and TGF-β1 could further enhance the activation of TAK1. Furthermore, the prolonged co-stimulation Fig. 4 The up-regulation of TGF-β receptors contributes to the gradually enhanced activation of TAK1 during long-lasting co-stimulation. a-c MCF-7 cells were cultured in absence or presence of TGF-β1/TNF-α (left) for the indicated time. Or the cells were cultured for 6 days in presence of TGF-β1 and or TNF-α. The expression of TGF-βRI (a), and TGF-βRII (b) was detected by real-time RT-PCR. c The expression of TβRI and TβRII was detected by Western blot after 6-d culture (left). Relative expression of TβRI and TβRII were calculated after densitometry assay as standardized by β-actin (right). d MCF-7 cells were unstimulated or stimulated with TGF-β1/TNF-α in absence or presence of SIS3 (10 μM), QNZ (40 nM), SB203580 (SB, 10 μM), PD98059 (PD, 10 μM) and SP600125 (SP, 10 μM) for 6 days. The expression of TGF-βRI (left) and TGF-βRII (right) was detected by real-time RT-PCR. e-h MCF-7 cells were transducted with control, TβRI or TβRII shRNA lentivirus. And then the cells were selected for stable expression using puromycin. e The expression of TβRI and TβRII was detected by Western blot (left). Relative expression of TβRI and TβRII was calculated after densitometry assay as standardized by β-actin (right). f The phospho-TAK1, TAK1, phospho-Smad2, Smad2, phospho-Smad3 and Smad3 were detected by Western blot. g The activity of NF-κB was assayed as described in Methods. h The ratio of phosphorylated protein to total protein of p38 MAPK, ERK1/2 and JNK was calculated after densitometric analysis of the blots. Data are representative of three independent experiments, or pooled from three independent experiments. P values, * P < 0.05, **P < 0.01 gradually enhanced the sustained activation of TAK1 by gradually up-regulating TβRs. Following the enhanced activation of TAK1, the activation of Smad and non-Smad pathways was also sustained and gradually enhanced during the long-lasting co-stimulation. Inhibiting these pathways, especially TAK1, significantly blocked TNF-α/TGF-β1-induced EMT and invasiveness of breast cancer cells. These results identified TAK1 as the cross-road that mediates TGF-β1/TNF-α-induced EMT and invasiveness in breast cancer epithelial cells. Consistently, the critical function of TAK1 in the EMT The sustained activation of signaling pathways and upregulation of SLUG are required for inducing EMT and invasiveness in breast cancer cells. a and b MCF-7 cells were stimulated or unstimulated with TGF-β1 and TNF-α for 6 days in absence or presence of (5Z)-7-oxozeaenol. a The expression of E-cadherin and vimentin was detected by Western blot. b The cells were used for matrigel invasion assay. c and d MCF-7 cells were stimulated or unstimulated with TGF-β1 and TNF-α for 6 days in absence or presence of SIS3, QNZ, SB203580, PD98059 and SP600125 for 6 days. c The expression of E-cadherin and vimentin was detected by Western blot (left). Relative expression of Ecadherin and vimentin were calculated after densitometry assay as standardized by β-actin (right). d The cells were used for matrigel invasion assay. e MCF-7 cells were cultured in presence of TGF-β1 and/or TNF-α for 6 days. The expression of SLUG, SNAIL, ZEB1 and TWIST1 was detected by real-time RT-PCR. f-h MCF-7 cells were transducted with control or SLUG shRNA lentivirus, and then selected for stable expression using puromycin. f The expression of SLUG, E-cadherin, vimentin and β-actin was detected by Western blot. g Relative expression of SLUG, E-cadherin and vimentin were calculated after densitometry assay as standardized by β-actin. h The cells were used for matrigel invasion assay. Data are representative of three independent experiments, or pooled from three independent experiments. P values, * P < 0.05, **P < 0.01 process was also reported in bronchiolitis epithelial and mesothelial cells (Gardner et al. 2012; Strippoli et al. 2012) . Although the critical role of TAK1 in inducing EMT has been widely accepted, the mechanisms underlying the modulatory effect of TAK1 in signaling pathways have not been fully understood. It has been identified that TAK1 can modulate the activation of NF-κB and MAPK (Neil and Schiemann 2008; Sakurai et al. 1999; Yamaguchi et al. 1995) , but the impact of TAK1 on Smad3 activation remains debatable. JNK/c-Jun, but not Smad3, was found to be the downstream and effective signal of TAK1 in a EMT model driven by TGF-β1 and accentuated by TNF-α (Gardner et al. 2012) . However, in this study, for the TGF-β1-insensitive cells, TAK1 can modulate the activation of Smad2/3, NF-κB and MAPKs which are induced by TGF-β1/TNF-α. Our results also showed that these signaling pathways, but not JNK pathway, are critical for TGF-β1/TNF-α-induced EMT. It implies that the modulatory effect of TAK1 may be diverse in different experimental models. In agreement with our results, a previous study showed that inhibiting TAK1 can suppress multiple signaling pathways, including the phosphorylation and transcriptional activation of Smad3 in mesothelial cells (Strippoli et al. 2012) . On the other hand, TAK1 can indirectly enhance the transcriptional activity of Smad3 by promoting the degradation of Smad3 inhibitory molecule SnoN (Kajino et al. 2007 ).
EMT-related transcriptional factors were reported to directly contribute to the EMT of breast cancer cells (Foroni et al. 2012) . Our data showed that the expression of SLUG was exclusively up-regulated after co-stimulation with TGF-β1 and TNF-α. Both Smad and ERK pathways were reported to induce the expression of SLUG (Joseph et al. 2009; Xu et al. 2009 ). Therefore, TGF-β1 and TNF-α could promote SLUG expression by activating both Smad and ERK pathways. On the other hand, SLUG could promote the expression of TGF-βRII (Dhasarathy et al. 2011) . In line with this, SLUG also forms a positive feed-back effect to enhance the activation of signaling pathways induced by TGF-β1 and TNF-α. Importantly, silencing SLUG nearly abolished TGF-β1/ TNF-α-induced EMT and invasiveness. Functionally, SLUG could not only suppress the expression of E-cadherin directly, but also activate another EMT transcriptional factor ZEB1 to lead to EMT indirectly (Joseph et al. 2009 ). Therefore, the upregulation of SLUG contributes to the TGF-β1/TNF-α-induced EMT and invasiveness of breast cancer cells.
In summary, in this study we demonstrated that TGF-β1 cooperates with TNF-α to promote the up-regulation of TβRs, thus inducing the sustained activation of TAK1 and the following activation of Smad2/3, NF-κB and MAPKs signaling pathways. All of these pathways, except for JNK, were required for TGF-β1/TNF-α-induced EMT and invasiveness of breast cancer cells. These findings highlight the importance of sustained activation of signaling pathways in the EMT and invasiveness of tumor cells. So inhibiting these signaling pathways, especially TAK1, may effectively suppress the EMT of tumor cells, thereby inhibiting the metastatic potential of tumor cells.
